EHA 2019 | Major AML treatment landscape changes

Christoph Röllig

Christoph Röllig, MD, Dresden University of Technology, Dresden, Germany, describes the breaking down of diagnostic and treatment algorithms to aid in the selection of front-line de novo acute myeloid leukemia (AML) therapy. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video